奥园健康(03662.HK)拟不超6.91亿元收购医美公司浙江连天美企业55%股权
格隆汇9月18日丨奥园健康(03662.HK)公告，于2020年9月18日，买方广东欣粤容产业投资有限公司（公司间接全资附属公司）与卖方广州盛妆医疗美容投资有限公司就收购事项订立买卖协议，买方已有条件同意收购目标公司浙江连天美企业管理有限公司的55%股权，现金代价上限为人民币6.91亿元。
目标公司为一间于中国注册成立的有限公司，而目标集团主要于中国从事提供医美服务业务。于本公告日期，卖方及买方分别持有目标公司的55%及5%股权。
公司表示，目标集团为中国领先的医美综合服务集团，提供医美行业的综合服务，包括美容手术服务、微创美容服务及美容皮肤服务。其目前于中国经营两家私人医美医院，即杭州华山连天美医疗美容医院及杭州维多利亚医疗美容医院，该两家医院的总营运面积为约30,000平方米，均获授予5A级管理标准并拥有标准医疗机构营运资质（其中包括由杭州华山连天美医疗美容医院取得的四级（高难度）手术资质）。
截至本公告日期，目标集团拥有合共24项注册专利，其中一项与下颌角有关的注册专利于参与整形专利国际巡展（韩国站）期间获韩国知识产权局授予发明专利。作为对其强大的技术能力、行业领先品牌及竞争力的认可，目标集团荣获60多项奖项及荣誉，并拥有逾300,000名客户。受益于中国医美市场的快速增长及凭藉其知名品牌声誉以及累积逾35年丰富行业经验及专业知识，目标公司已成为中国浙江省医美行业的龙头企业。
董事认为收购事项乃集团进一步发展医美业务及拓阔及多元化收入来源的良机，此与集团补充其物业管理服务及商业运营服务的发展策略一致。此外，董事一直积极物色合适的投资机遇以为股东实现更佳的回报。监于目标集团的品牌声誉及经营业绩，公司认为收购事项将进一步促成集团与目标集团间的战略合作并提升现有协同效益，从而推动集团的业务增长及增强集团的盈利能力，进而提升股东回报。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
